Veracyte Quarterly Cash Flow Statement
NASDAQ: VCYTHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Veracyte free cash flow
In the quarter ended Jun 30, 2026, Veracyte generated $45.8 million of operating cash flow and spent $2.9 million on capital expenditures. That left free cash flow of $43.0 million, a free-cash-flow margin of 28.6% of revenue. Free cash flow was up 32.9% from the prior year's $32.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Veracyte cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 25.49M | 28.71M | 41.15M | 19.14M | -980.00K | 7.05M | 5.11M | 15.15M | 5.73M | -1.86M | -28.29M | -29.62M |
| Net Income growth (YoY) | — | +307.36% | +704.79% | +26.28% | -117.09% | — | — | — | — | — | — | — |
| Depreciation & Amortization | 4.84M | 5.43M | 5.30M | 5.27M | 5.49M | 5.36M | 6.25M | 5.88M | 5.74M | 5.59M | 6.34M | 7.32M |
| Stock-Based Compensation | 14.09M | 12.76M | 10.90M | 10.76M | 10.98M | 10.96M | 9.63M | 8.75M | 9.85M | 8.02M | 7.51M | 7.26M |
| Change in Working Capital | -4.11M | -4.29M | 6.80M | -3.97M | -4.33M | -5.16M | -2.50M | 1.87M | -4.20M | -13.04M | -20.00K | -1.21M |
| Operating Cash Flow | 45.83M | 35.22M | 52.58M | 44.76M | 33.60M | 5.36M | 24.52M | 29.96M | 29.57M | -8.97M | 15.55M | 14.17M |
| Capital Expenditures | -2.86M | -2.96M | -3.78M | -2.79M | -1.29M | -1.82M | -4.14M | -2.24M | -2.77M | -2.13M | -2.50M | -2.80M |
| Investing Cash Flow | -13.54M | -127.96M | -5.43M | 48.26M | -224.00K | -51.82M | -54.14M | -2.24M | -2.77M | 2.88M | -2.50M | -2.80M |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Financing Cash Flow | 4.14M | -6.63M | -149.00K | 2.98M | -566.00K | -6.48M | -4.51M | 10.29M | -11.00K | -864.00K | 645.00K | 110.00K |
| Net Change in Cash | 36.39M | -99.43M | 47.02M | 96.06M | 33.39M | -52.87M | -34.53M | 38.16M | 26.73M | -7.06M | 14.00M | 11.30M |
| Free Cash Flow | 42.97M | 32.25M | 48.80M | 41.97M | 32.32M | 3.54M | 20.38M | 27.72M | 26.80M | -11.10M | 13.05M | 11.37M |
This table shows 12 quarterly periods of Veracyte's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VCYT's reporting calendar. What is a cash flow statement?